Study details
Enrolling now
Dendritic Cell Vaccine Trial
H. Lee Moffitt Cancer Center and Research Institute
NCT IDNCT05809752ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
18
Study length
about 2.6 years
Ages
18+
Locations
3 sites in FL, NY
What this study is about
This trial is testing a new vaccine, Dendritic Cell Vaccine (DCV), to see how it works in people with breast cancer and leptomeningeal disease. The goal is to find the safest dose of this vaccine.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Dendritic Cell Vaccine
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
vaccine
Drug routes
injection
Endpoints
Primary: Maximum Tolerated Dose of Intrathecal Dendritic Cell Vaccine
Secondary: Overall Survival, Progression Free Survival
Body systems
Oncology